PDCD1 and cancer: In addition, patients in Cluster 1 or the low-CRRS group appeared to have more enriched CD8+ T cells, which can influence the PD-1/PD-L1-related immune inhibitory axis to disrupt immune tolerance and kill cancer cells as well as strengthen the immunotherapy response [6, 30].